Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma 2026-05-21 · Financial Post About Toripalimab Read MoreVisit freshyourfeel.org for more information. Read at source